AZD7789 for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Research Site, Nashville, TNNon-Small Cell Lung CancerAZD7789 - Drug
Eligibility
18 - 130
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective.

Treatment Effectiveness

Study Objectives

3 Primary · 11 Secondary · Reporting Duration: From first documented response to confirmed progressive disease or death; approximate duration of 4 years.

Year 4
Disease control rate
Duration of response
Year 4
Progression-free survival
Year 4
Overall survival
Year 4
Immunogenicity of AZD7789
Year 4
Pharmacokinetics of AZD7789: Area Under the concentration-time curve (AUC)
Pharmacokinetics of AZD7789: Clearance
Pharmacokinetics of AZD7789: Maximum plasma concentration of the study drug (Cmax)
Pharmacokinetics of AZD7789: Terminal elimination half-life (t 1/2)
Preliminary anti-tumour activity of AZD7789: Changes in circulating tumor DNA (ctDNA)
Year 4
Objective response rate
Preliminary anti-tumour activity of AZD7789
Month 18
Number of participants with dose-limiting toxicity (DLT), as defined in the protoocol
Day 90
Number of participants with adverse events (AE), serious adverse events (SAE) and immune-mediated AEs (imAE)

Trial Safety

Trial Design

4 Treatment Groups

Dose Escalation Part A: NSCLC Immuno-oncology (IO) acquired or primary resistanc...
1 of 4
Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) ...
1 of 4
Dose Expansion Part B2: NSCLC IO naive
1 of 4
Dose Expansion Part B1: NSCLC IO acquired resistance
1 of 4

Experimental Treatment

81 Total Participants · 4 Treatment Groups

Primary Treatment: AZD7789 · No Placebo Group · Phase 1 & 2

Dose Escalation Part A: NSCLC Immuno-oncology (IO) acquired or primary resistance
Drug
Experimental Group · 1 Intervention: AZD7789 · Intervention Types: Drug
Dose Escalation Part A: Non small cell lung cancer (NSCLC) Immuno-oncology (IO) acquired resistance
Drug
Experimental Group · 1 Intervention: AZD7789 · Intervention Types: Drug
Dose Expansion Part B2: NSCLC IO naive
Drug
Experimental Group · 1 Intervention: AZD7789 · Intervention Types: Drug
Dose Expansion Part B1: NSCLC IO acquired resistance
Drug
Experimental Group · 1 Intervention: AZD7789 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: from first documented response to confirmed progressive disease or death; approximate duration of 4 years.

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,018 Previous Clinical Trials
240,376,773 Total Patients Enrolled

Eligibility Criteria

Age 18 - 130 · All Participants · 19 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are there any vacancies open to participants in this clinical trial?

"Affirmative. The information located on clinicaltrials.gov implies that this medical trial is in the process of enrolling participants. It was initially published on September 28th 2021 and most recently updated on November 17th 2022; with 81 patients to be enrolled from 4 different locations." - Anonymous Online Contributor

Unverified Answer

Is this trial open to participants of the geriatric age range?

"According to the requirements, individuals between 18 and 130 years old can apply for this medical research. There are 21 trials specifically designed for a younger cohort while 1358 studies target elderly patients." - Anonymous Online Contributor

Unverified Answer

What benefits are anticipated from this research?

"According to AstraZeneca, the clinical trial's primary endpoint is evaluating the anti-tumour activity of AZD7789 over a span of 18 months. Additionally, secondary endpoints such as duration of response, immunogenicity and pharmacokinetic measurements will also be evaluated." - Anonymous Online Contributor

Unverified Answer

How many participants are included in this clinical experiment?

"Affirmative, according to clinicaltrials.gov the trial posted on September 28th 2021 is currently in progress. The most recent update was made on November 17th 2022 and 81 participants are hoped to be recruited from 4 different medical locations." - Anonymous Online Contributor

Unverified Answer

Are any locations in North America hosting this experiment?

"At the moment, 4 sites are taking on participants in this trial; Toronto, New York and Nashville being a few of them. To limit travelling needs during your involvement, select the closest site possible to you." - Anonymous Online Contributor

Unverified Answer

Is it possible to join this research program?

"This clinical trial is currently recruiting 81 individuals with carcinoma, non-small cell lung. To be eligible for the study, participants must meet the following criteria: age between 18 and 130; histologically or cytologically documented Stage IIIB to IV NSCLC that cannot be cured by surgery or radiation; ECOG performance status of 0 or 1; not pregnant (women) and willing to avoid pregnancy (or men willing to use highly effective contraception); adequate organ and bone marrow function measured within 28 days before first dose; squamous/non-squamous NSCLC diagnoses accepted but at least one prior line of systemic therapy containing approved PD" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.